To be considered for funding, applications for the FY19 LCRP Translational Research Partnership Award must address at least one of the nine Areas of Emphasis listed below:
• Identify innovative strategies for the screening and early detection of lung cancer.
• Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• Identify innovative strategies for prevention of the occurrence of lung cancer.
• Identify innovative strategies for the treatment of lung cancer.
• Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer
• Develop or optimize predictive markers to assist with therapeutic decision-making.
• Understand mechanisms of resistance to treatment (primary and secondary).
• Understand contributors to lung cancer development other than tobacco.
• Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).
• PIs must be at or above the level of Assistant Professor (or equivalent).
• The clinician must be an M.D., M.D./Ph.D., or equivalent with clinical duties and/or responsibilities.
The anticipated direct costs budgeted for the entire period of performance for an FY19 LCRP Translational Research Partnership Award will not exceed $900,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.